2023 World Conference on Lung Cancer (Posters)-P2.09. Risk of Recurrent Interstitial Lung Disease (ILD) from EGFR TKI Rechallenge after Osimertinib Induced ILD

P2.09. Risk of Recurrent Interstitial Lung Disease (ILD) from EGFR TKI Rechallenge after Osimertinib Induced ILD - PDF(Abstract)

Back to course

Pdf Summary

This study focused on the risk of recurrent interstitial lung disease (ILD) from EGFR tyrosine kinase inhibitor (TKI) rechallenge after Osimertinib-induced ILD in patients with metastatic non-small cell lung cancer (NSCLC). Osimertinib is commonly used as a first-line treatment for EGFR mutation-positive NSCLC. However, it can lead to ILD, which is a potentially life-threatening complication. The objective of the study was to evaluate the safety of EGFR TKI rechallenge in patients who developed Osimertinib-induced ILD.<br /><br />A retrospective review was conducted on patients treated with Osimertinib at a tertiary institution from 2017 to 2022. Patients who developed Osimertinib-induced ILD with a severity grade of 2 or above were included in the study. A total of 27 patients out of 799 (3.4%) fulfilled the inclusion criteria.<br /><br />The results showed that the median age of the patients was 69 years, and nearly half of them received Osimertinib as their first-line treatment. The incidence of grade 2, 3/4, and 5 ILD was 33%, 48%, and 19%, respectively. The median time to onset of ILD was 9 weeks. Among the patients who received first-line Osimertinib and were retreated with Erlotinib, only one had recurrent ILD. In contrast, four out of five patients who received Osimertinib rechallenge had recurrent ILD, with three of them experiencing grade 5 events.<br /><br />Based on these findings, the study concludes that the risk of recurrent ILD is significantly higher with Osimertinib rechallenge compared to Erlotinib rechallenge. Therefore, it suggests that EGFR TKI rechallenge with Erlotinib may be considered, while rechallenge with Osimertinib should be prohibited in patients with grade 2 or above Osimertinib-induced ILD.<br /><br />In summary, this study highlights the safety concerns associated with EGFR TKI rechallenge in patients with Osimertinib-induced ILD. The findings suggest that cautious consideration should be given to the choice of EGFR TKIs in this patient population to minimize the risk of recurrent ILD.

Asset Subtitle

Molly Li

Meta Tag

Speaker Molly Li

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

risk

recurrent interstitial lung disease

ILD

EGFR tyrosine kinase inhibitor

TKI rechallenge

Osimertinib-induced ILD

metastatic non-small cell lung cancer

NSCLC

safety

Erlotinib